<DOC>
	<DOCNO>NCT02840721</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy PF-06480605 subject moderate severe ulcerative colitis .</brief_summary>
	<brief_title>Safety , Efficacy , Tolerability Study PF-06480605 Subjects With Moderate Severe Ulcerative Colitis .</brief_title>
	<detailed_description>This Phase 2a , single arm , two-stage study subject moderate severe ulcerative colitis . Subjects receive 500 mg PF-06480605 intravenously every 2 week total 7 dos . Blood , stool , tissue sample collect various time point throughout study evaluate safety , tolerability , efficacy , pharmacokinetics , immunogenicity . Duration participation subject approximately 8 month .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female subject ≥ 18 ≤ 75 year age time inform consent Male subject able father child female subject childbearing potential must agree use two highly effective method contraception throughout study Week 26 visit Diagnosis ulcerative colitis ≥ 4 month Subjects moderate severe active ulcerative colitis define screen colonoscopy total Mayo score ≥ 6 , rectal bleeding subscore ≥ 1 , endoscopic subscore ≥ 2 Mayo Active disease beyond rectum ( &gt; 15 cm active disease screen colonoscopy ) Must inadequate response , loss response , intolerance least one conventional therapy ulcerative colitis : Steroids ; Immunosuppressants ( AZA , 6MP , MTX ) ; Anti TNF inhibitor ( eg , infliximab , adalimumab , golimumab ) ; Antiintegrin inhibitor ( eg , vedolizumab ) . Subjects currently receive follow treatment eligible provide stable dos Oral 5ADA sulfasalazine least 4 week prior baseline ; oral corticosteroid stable dose least 2 week prior baseline ; 6MP AZA stable dose 8 week prior baseline . Diagnosis indeterminate colitis , ischemic colitis , radiation colitis , diverticular disease associate colitis , microscopic colitis Crohn 's Disease . Subjects clinical finding suggestive Crohn 's disease ( eg , fistulae , granulomas biopsy ) also exclude . Subjects colonic dysplasia neoplasia , toxic megacolon , primary sclerosing cholangitis , know colonic stricture , history colonic small bowel stoma , history colonic small bowel obstruction resection Presence active enteric infection ( positive stool culture sensitivity ) Known history HIV base document history positive serological test , positive HIV serologic test screen Presence transplant organ Cancer history cancer lymphoproliferative disease within previous 5 year ( resect cutaneous basal cell squamous cell carcinoma treat evidence recurrence ) ; Acute coronary syndrome ( eg. , myocardial infarction , unstable angina pectoris ) ; Any history cerebrovascular disease within 24 week screen ; Subject current history QT prolongation Class III Class IV heart failure Prior evidence liver injury toxicity due methotrexate Abnormality hematology and/or chemistry profile screen ( detailed protocol ) Subjects receive follow therapy within designated time period : &gt; 9 mg/day oral budesonide &gt; 20 mg/day prednisone equivalent within 2 week prior baseline IV , IM ( parenteral ) , topical ( rectal ) treatment 5ASA corticosteroid enemas/suppositories within 2 week prior baseline Biologics include antiTNF inhibitor describe : Infliximab , Adalimumab , Golimumab within 8 week prior baseline Antiintegrin inhibitor ( eg , vedolizumab ) within 12 week prior baseline Other investigational procedure product , live attenuate vaccine within 30 day prior baseline . Current history ( within 2 year ) serious psychiatric disease alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>